Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s share price hit a new 52-week low on Thursday . The stock traded as low as C$0.85 and last traded at C$0.90, with a volume of 42054 shares trading hands. The stock had previously closed at C$0.91.
Medicenna Therapeutics Stock Performance
The firm has a market cap of C$68.08 million, a P/E ratio of -2.51 and a beta of 1.21. The stock's 50 day moving average is C$1.02 and its two-hundred day moving average is C$1.21. The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65.
Medicenna Therapeutics Company Profile
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
